Auto-SCT for AML in second remission: CALGB study 9620.
- Citation:
- Bone Marrow Transplant vol 44 (6) 353-9
- Year:
- 2009
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- CA02599, CA03927, CA04457, CA07968, CA21060, CA26806, CA29165, CA31946, CA31983, CA33601, CA35279, CA41287, CA45808, CA47559, CA47577, CA60138, CA77406, CA77440, CA77658
- Corr. Author:
- Authors:
- C A Linker K Owzar B Powell D Hurd L E Damon L E Archer R A Larson
- Networks:
- Study
- CALGB-9620
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Adult, Aged, Aging, Antigens, CD34, Antimetabolites, Antineoplastic, Antineoplastic Agents, Phytogenic, Combined Modality Therapy, Cytarabine, Disease-Free Survival, Etoposide, Female, Humans, Ideal Body Weight, Infusions, Intravenous, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute, Male, Middle Aged, Peripheral Blood Stem Cell Transplantation, Remission Induction, Transplantation, Autologous, Treatment Outcome, Treatment Refusal, Young Adult